Results for genotypically translation from English to Maltese

genotypically resistant
Ġenotipikament reżistenti

the rate of genotypically confirmed telbivudine resistance in the pivotal study at 48 weeks was 2.7%.
ir- rata ta ’ reżistenza għal telbivudine li ġiet konfermata b’ mod ġenotopiku fi studju pivitali fit - 48 ġimgħa kienet 2. 7%.

fas pp - with enf (fas) - without enf (fas) genotypically resistant lpv/ rtv
- b' enf (fas)

treatment response is presented for the overall population (displayed by enfuvirtide use), and detailed by pi strata for the subgroup of patients with genotypically resistant strains in the table below.
ir- rispons għat- trattament hu preżentat għall- popolazzjoni globali (murija bl- użu ta 'enfuvirtide), u dettaljata bi strata ta' pi għas- sottogrupp ta 'pazjenti b' razez ġenotipikament reżistenti fit- tabella hawn isfel.

resist data also demonstrate that aptivus co- administered with low dose ritonavir exhibits a better treatment response at 48 weeks when the obr contains genotypically available antiretroviral agents (eg enfuvirtide).
id- dejta minn resist turi wkoll li meta aptivus jiġi mogħti flimkien ma 'doża baxxa ta' ritonavir ikun hemm rispons għat- trattament aħjar fl- 48 ġimgħa meta l- obr ikun fih mediċini ġenotipiċi antiretrovirali disponibbli (eg enfuvirtide).

in healthy subjects who are genotypically poor metabolisers of cyp2d6 substrates (used as a surrogate for cyp2d6 inhibition), mean cmax and aucinf of a single 160 mg dose of a mirabegron ir formulation were 14% and 19% higher than in extensive metabolisers, indicating that cyp2d6 genetic polymorphism has minimal impact on the mean plasma exposure to mirabegron.
f‟suġġetti b‟saħħithom li huma ġenotipikament metabolizzaturi dgħajfa tas-substrati cyp2d6 (użati bħala sostituti għall-inibizzjoni cyp2d6), il-medja ta‟ cmax u aucinf ta‟ doża waħda ta‟ 160 mg ta‟ formulazzjoni mirabegron ir kienu 14% u 19% ogħla milli f‟metabolizzaturi estensivi, u dan jindika li l-polimorfiżmu ġenetiku cyp2d6 għandu impatt minimu fuq l-esponiment medju tal-plażma għal mirabegron.